NCT00713011撤回3 期
Randomized Open-label 2-arm Parallel Design Comparator Study of the Effect of Adalat® XL® Compared to Diltiazem on Proteinuria and Blood Pressure in Patients With Diabetes and Mild to Moderate Hypertension When Used as an Add on to Avalide®
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 发起方
- Bayer
- 主要终点
- Change in Proteinuria
研究概览
简要总结
The study consists of a 12 week run-in period when all subjects are stabilized on a single dose of Avalide (300 mg/12.5 mg or 300mg/25mg dose) per day. After this 12 week run-in ends, subjects will be randomly assigned to start the addition of either Adalat XL or Tiazac XC for 18 weeks of treatment. Subjects will have a 1 in 2 chance of receiving the study drug Adalat XL and a 1 in 2 chance of receiving the drug Tiazac XC. An end of treatment visit will be done 18 weeks after start of study drug. The expected duration of the study is 30 weeks. The purpose of this study is to compare the change in proteinuria, through a urine test, while taking study drug until high blood pressure (BP) is reduced to near normal levels in study subjects with diabetic nephropathy and hypertension.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •>/= 18 and < 80 years old.
- •Diagnosed with hypertension.
- •Diagnosed with diabetes mellitus type 2 for at least 6 mths prior to entry and on stable medication for diabetes for at 1 mth prior to screening.
- •Treated on ARB, ACE inhibitor with or without hydrochlorothiazide and suitable to receive combination therapy with Avalide at 300mg/12.5mg per day or 300mg/25mg per day.
- •Diagnosed with diabetic nephropathy and have proteinuria between 0.8g/day and 5.0g/day at screening and then between 0.8g/day and 3.0g/day at randomization.
- •Medically appropriate to receive Adalat XL or Tiazac XC.
排除标准
- •History of alcohol or substance abuse.
- •Significant CV disorder such as ischemic heart disease, arrhythmias within the last 6 mths, or any history of severe congestive heart failure.
- •Myocarditis or pericarditis within last 30 day of screening.
- •ECG showing evidence of major arrhythmia or conduction disturbances requiring treatment with anti-arrhythmic medication.
- •Females with child-bearing potential or males with a partner of child-bearing potential unless willing to use effective contraception during the study and 3 mths after the end of study.
- •Females who are pregnant, lactating or planning pregnancy during the study and for 3 mths after the study end.
- •Known hypersensitivity to Adalat XL or Tiazac XC or other calcium channel blockers of the dihydropyridine class.
- •Resting heart rate <50 or >110 bpm.
- •Presence of secondary or malignant hypertension.
- •DBP >/= 180 and/or SBP >/= 110 mmHg.
研究组 & 干预措施
Arm 1
Experimental
干预措施: Adalat XL (Drug)
Arm 2
Active Comparator
干预措施: Tiazac XC (Drug)
结局指标
主要结局
Change in Proteinuria
时间窗: Baseline/Randomization to Week 18
次要结局
- Percentage of subjects reaching a BP target of 130/80 mmHg at Week 18(Baseline/Randomization to Week 18)
- Number and doses of anti-hypertensives used in the 2 treatment arms(Baseline/Randomization to Week 18)
- Levels of urinary albumin and protein content and estimated glomerular filtration rate (GFR) in the 2 treatment groups(Baseline/Randomization to Week 18)
- Early BP reduction from randomization achieved with the starting dose in the 2 treatment arms(Baseline/Randomization to Week 1)
- Adverse Events leading to early withdrawal(Screening to end of study)
- All Adverse Events especially, edema(Screening to end of study)
- Change in index of glycemia (HbA1c)(Screening to Week 18)
研究者
相似试验
已完成
3 期
Multicenter Study in Postmenopausal Women With Osteoporosis, ALVOBONDOsteoporosis, PostmenopausalNCT05395091Alvotech Swiss AG532
已完成
4 期
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)Pulmonary Disease, Chronic ObstructiveNCT02236611GlaxoSmithKline1,036
已完成
1 期
Comparative Pharmacokinetic Study of Pirfenidone Modified-Release Tablets in Healthy Subjects Under Fasting and Fed ConditionsIdiopathic Pulmonary FibrosisNCT06569381Overseas Pharmaceuticals, Ltd.18
已完成
1 期
Single Dose Comparability Study of New and Current Dupilumab Drug Products Subcutaneously Administered in Healthy AdultsHealthy VolunteersNCT05976386Sanofi182
已完成
1 期
A Randomized, Open-Label, Parallel-Design Pharmacokinetic and Pharmacodynamic Interaction Study of TNM002 and Adsorbed Tetanus VaccineTetanusNCT06607380Zhuhai Trinomab Pharmaceutical Co., Ltd.60